Education
About Us
Working with TipRanks
Follow Us
IRLAB Therapeutics AB Class A (SE:IRLAB.A)
:IRLAB.A
Total Valuation
IRLAB Therapeutics AB Class A has a market cap or net worth of kr162.74M. The enterprise value is kr225.44M.
Market Capkr162.74M
Enterprise Valuekr225.44M
Share Statistics
IRLAB Therapeutics AB Class A has 84,858,246 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding84,858,246
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
IRLAB Therapeutics AB Class A’s return on equity (ROE) is -2.55 and return on invested capital (ROIC) is -80.72%.
Return on Equity (ROE)-2.55
Return on Assets (ROA)-0.61
Return on Invested Capital (ROIC)-80.72%
Return on Capital Employed (ROCE)-2.08
Revenue Per Employee3.05M
Profits Per Employee-2.68M
Employee Count31
Asset Turnover0.69
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of IRLAB Therapeutics AB Class A is ―. IRLAB Therapeutics AB Class A’s PEG ratio is 0.13.
PE Ratio―
PS Ratio5.89
PB Ratio17.09
Price to Fair Value17.09
Price to FCF-8.48
Price to Operating Cash Flow-1.58
PEG Ratio0.13
Income Statement
In the last 12 months, IRLAB Therapeutics AB Class A had revenue of 94.63M and earned -83.13M in profits. Earnings per share was -1.60.
Revenue94.63M
Gross Profit-92.42M
Operating Income-75.11M
Pretax Income-83.13M
Net Income-83.13M
EBITDA-68.07M
Earnings Per Share (EPS)-1.60
Cash Flow
In the last 12 months, operating cash flow was -53.65M and capital expenditures 0.00, giving a free cash flow of -53.65M billion.
Operating Cash Flow-53.65M
Free Cash Flow-53.65M
Free Cash Flow per Share-0.63
Dividends & Yields
IRLAB Therapeutics AB Class A pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.10
52-Week Price Change-81.49%
50-Day Moving Average2.29
200-Day Moving Average4.18
Relative Strength Index (RSI)36.88
Average Volume (3m)244.46K
Important Dates
IRLAB Therapeutics AB Class A upcoming earnings date is Feb 11, 2026, TBA (Confirmed).
Last Earnings DateOct 29, 2025
Next Earnings DateFeb 11, 2026
Ex-Dividend Date―
Financial Position
IRLAB Therapeutics AB Class A as a current ratio of 0.80, with Debt / Equity ratio of -273.65%
Current Ratio0.80
Quick Ratio0.80
Debt to Market Cap0.10
Net Debt to EBITDA0.10
Interest Coverage Ratio-7.17
Taxes
In the past 12 months, IRLAB Therapeutics AB Class A has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
IRLAB Therapeutics AB Class A EV to EBITDA ratio is -8.10, with an EV/FCF ratio of -8.38.
EV to Sales5.82
EV to EBITDA-8.10
EV to Free Cash Flow-8.38
EV to Operating Cash Flow-8.40
Balance Sheet
IRLAB Therapeutics AB Class A has kr110.13M in cash and marketable securities with kr29.81M in debt, giving a net cash position of kr80.33M billion.
Cash & Marketable Securitieskr110.13M
Total Debtkr29.81M
Net Cashkr80.33M
Net Cash Per Sharekr0.95
Tangible Book Value Per Share-kr0.27
Margins
Gross margin is -28.58%, with operating margin of -79.38%, and net profit margin of -87.85%.
Gross Margin-28.58%
Operating Margin-79.38%
Pretax Margin-87.85%
Net Profit Margin-87.85%
EBITDA Margin-71.93%
EBIT Margin-76.78%
Analyst Forecast
The average price target for IRLAB Therapeutics AB Class A is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target―
Price Target Upside―
Analyst ConsensusModerate Sell
Analyst Count0
Revenue Growth Forecast69.03%
EPS Growth Forecast23.10%